These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 36066501

  • 1. Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Senet P, Maillard H, Diot E, Lazareth I, Blaise S, Arnault JP, Pistorius MA, Boulon C, Cogrel O, Warzocha U, Rivière S, Malloizel-Delaunay J, Servettaz A, Sassolas B, Viguier M, Monfort JB, Janique S, Vicaut E, BRASS collaborators.
    Arthritis Rheumatol; 2023 Mar; 75(3):459-467. PubMed ID: 36066501
    [Abstract] [Full Text] [Related]

  • 2. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
    Motegi S, Yamada K, Toki S, Uchiyama A, Kubota Y, Nakamura T, Ishikawa O.
    J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
    [Abstract] [Full Text] [Related]

  • 3. The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Bello RJ, Cooney CM, Melamed E, Follmar K, Yenokyan G, Leatherman G, Shah AA, Wigley FM, Hummers LK, Lifchez SD.
    Arthritis Rheumatol; 2017 Aug; 69(8):1661-1669. PubMed ID: 28426903
    [Abstract] [Full Text] [Related]

  • 4. The efficacy of botulinum toxin A in the treatment of Raynaud's phenomenon in systemic sclerosis: A randomized self-controlled trial.
    Du W, Zhou M, Zhang C, Sun Q.
    Dermatol Ther; 2022 Jul; 35(7):e15529. PubMed ID: 35441772
    [Abstract] [Full Text] [Related]

  • 5. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM, Korn JH, Csuka ME, Medsger TA, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR.
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [Abstract] [Full Text] [Related]

  • 6. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J, Legré R, Veit V, Guardia C, Gay AM.
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.
    Denton CP, Hachulla É, Riemekasten G, Schwarting A, Frenoux JM, Frey A, Le Brun FO, Herrick AL, Raynaud Study Investigators.
    Arthritis Rheumatol; 2017 Dec; 69(12):2370-2379. PubMed ID: 29193819
    [Abstract] [Full Text] [Related]

  • 8. Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience.
    Nagarajan M, McArthur P.
    Rheumatol Int; 2021 May; 41(5):943-949. PubMed ID: 32447423
    [Abstract] [Full Text] [Related]

  • 9. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud's syndrome associated with scleroderma.
    Uppal L, Dhaliwal K, Butler PE.
    J Hand Surg Eur Vol; 2014 Oct; 39(8):876-80. PubMed ID: 24369360
    [Abstract] [Full Text] [Related]

  • 10. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
    Correa MJ, Mariz HA, Andrade LE, Kayser C.
    Rev Bras Reumatol; 2014 Oct; 54(6):452-8. PubMed ID: 25458027
    [Abstract] [Full Text] [Related]

  • 11. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A, Abou-Raya S, Helmii M.
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [Abstract] [Full Text] [Related]

  • 12. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM, Halkier-Sørensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, Banga JD, Watson HR.
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [Abstract] [Full Text] [Related]

  • 13. Optimisation of botulinum toxin type a treatment for the management of Raynaud's phenomenon using a dorsal approach: a prospective case series.
    Dhaliwal K, Griffin MF, Salinas S, Howell K, Denton CP, Butler PEM.
    Clin Rheumatol; 2019 Dec; 38(12):3669-3676. PubMed ID: 31482318
    [Abstract] [Full Text] [Related]

  • 14. Botulinum toxin in the management of primary and secondary Raynaud's phenomenon.
    Ennis D, Ahmad Z, Anderson MA, Johnson SR.
    Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101684. PubMed ID: 33965340
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
    Motegi SI, Uehara A, Yamada K, Sekiguchi A, Fujiwara C, Toki S, Date Y, Nakamura T, Ishikawa O.
    Acta Derm Venereol; 2017 Jul 06; 97(7):843-850. PubMed ID: 28358168
    [Abstract] [Full Text] [Related]

  • 16. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.
    Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, Phillips K, Seibold JR.
    J Rheumatol; 2009 Oct 06; 36(10):2264-8. PubMed ID: 19755613
    [Abstract] [Full Text] [Related]

  • 17. Calcium channel blockers for primary and secondary Raynaud's phenomenon.
    Rirash F, Tingey PC, Harding SE, Maxwell LJ, Tanjong Ghogomu E, Wells GA, Tugwell P, Pope J.
    Cochrane Database Syst Rev; 2017 Dec 13; 12(12):CD000467. PubMed ID: 29237099
    [Abstract] [Full Text] [Related]

  • 18. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes.
    Dhaliwal K, Griffin M, Denton CP, Butler PEM.
    BMJ Case Rep; 2018 Mar 09; 2018():. PubMed ID: 29525756
    [Abstract] [Full Text] [Related]

  • 19. Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary.
    Motegi SI, Sekiguchi A, Saito S, Ishibuchi H, Kishi C, Yasuda M, Ishikawa O.
    J Dermatol; 2018 Mar 09; 45(3):349-352. PubMed ID: 29164658
    [Abstract] [Full Text] [Related]

  • 20. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
    Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM.
    Arthritis Rheum; 1999 Dec 09; 42(12):2646-55. PubMed ID: 10616013
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.